Avalo Therapeutics, Inc. (AVTX) News
Track canonical SquawkNews coverage tagged to AVTX, Avalo Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. NASDAQ:AVTX, a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammator
NEWS | Sep 29, 2026, 08:08 PM UTC
H
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. NASDAQ:AVTX, a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammator
GEOPOLITICS | Sep 23, 2026, 11:02 AM UTC
H
AVTX - Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
AVTX - Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
GEOPOLITICS | Sep 23, 2026, 11:00 AM UTC
L
AVTX: Advancing anti-IL-1 beta therapy to phase III for HS, expanding indications, and securing strong financial support
A clinical-stage biotech is advancing its potent anti-IL-1 beta antibody, abdakibart, into phase III for HS after strong phase II results and positive physician feedback. Expansion plans include a long-acting version and
EQUITY | Sep 10, 2026, 01:37 PM UTC
L
AVTX: Robust phase IIb HS data and pipeline expansion drive confidence in upcoming phase III and beyond
Strong phase IIb results for abdakibart in HS support phase III advancement, with robust efficacy, favorable safety, and high physician enthusiasm. Expansion plans include a long-acting IL-1 beta antibody and new indicat
EQUITY | Sep 10, 2026, 12:51 PM UTC
L
Avalo Therapeutics grants inducement equity awards to six new employees
Avalo Therapeutics announced inducement equity awards to six new employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
Avalo Therapeutics announces inducement grants to new employees under Nasdaq Rule 5635(c)(4)
Avalo Therapeutics (AVTX) announced inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:05 PM UTC
L
Avalo Therapeutics to participate in upcoming investor conferences
AvaIо Therapeutics said management will participate in upcoming investor conferences, according to a company announcement.
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
AVTX - Avalo Therapeutics to Participate in Upcoming Investor Conferences
AVTX - Avalo Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
AVTX - Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
AVTX - Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
AVTX Avalo Therapeutics - selling stockholders may sell up to 128,189 shares of common stock - SEC filing
AVTX Avalo Therapeutics - selling stockholders may sell up to 128,189 shares of common stock - SEC filing
REGULATION | Jul 28, 2026, 08:44 PM UTC